NASDAQ:DNTH Dianthus Therapeutics Q3 2026 Earnings Results & Report $85.81 +3.11 (+3.76%) Closing price 04:00 PM EasternExtended Trading$85.82 +0.01 (+0.01%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Dianthus Therapeutics beat analyst expectations on both earnings and revenue in its Q3 2026 results, released November 4, 2026. The company reported EPS of -$0.81 versus the -$0.9445 consensus estimate, while revenue of $1.21 million topped the $461 thousand estimate by $749.00 thousand. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ3 2026Report DateNovember 4, 2026TimeAfter Market ClosesConference Call4:00 PM ET Dianthus Therapeutics EPS ResultsActual EPS-$0.81Consensus EPS -$0.9445Beat/MissBeat by +$0.1345One Year Ago EPSN/AEPS Beat Rate4 of last 8 quartersDianthus Therapeutics Revenue ResultsActual Revenue$1.21 millionExpected Revenue$461 thousandBeat/MissBeat by +$749.00 thousandYoY Revenue GrowthN/AConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Dianthus Therapeutics Q3 2026 Earnings FAQ Did Dianthus Therapeutics beat earnings estimates for Q3 2026? Dianthus Therapeutics (NASDAQ:DNTH) reported earnings of -$0.81 per share for Q3 2026, beating the consensus estimate of -$0.9445. The report was announced on Wednesday, November 4, 2026. What was Dianthus Therapeutics' revenue for Q3 2026? Dianthus Therapeutics reported revenue of $1.21 million for Q3 2026, against a consensus estimate of $461 thousand. Dianthus Therapeutics Earnings HeadlinesDianthus Therapeutics (DNTH) Projected to Announce Earnings on ThursdayNovember 4 at 3:57 AM | americanbankingnews.comDianthus Therapeutics Inc DNTHNovember 3 at 4:58 AM | morningstar.comMBank of America: 'Digital Dollar Inevitable'Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the digital dollar. They gave us the timeline… 2025 to 2030. We're in that window right now. Once the digital dollar launches, every transaction you make will be tracked. Your spending could be controlled. Your accounts could be frozen. Over 4,500 investors have already used this legal backdoor to hold assets CBDCs can't freeze and generate yields the Federal Reserve can't touch.November 4 at 1:00 AM | Decentralized Masters (Ad)Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)November 2 at 5:00 PM | globenewswire.comDianthus Therapeutics to Participate in Five Investor Conferences During NovemberNovember 2 at 4:01 PM | globenewswire.comDianthus Therapeutics, Inc. (NASDAQ:DNTH) Stock Now Rated "Buy" by Sell-Side BrokeragesNovember 2 at 1:46 AM | americanbankingnews.comSee More Dianthus Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Dianthus Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Dianthus Therapeutics and other key companies, straight to your email. Email Address About Dianthus TherapeuticsDianthus Therapeutics (NASDAQ:DNTH) is a clinical-stage biotechnology company focused on developing antibody-based medicines for autoimmune and inflammatory diseases. The company’s research centers on the complement system, an important part of the immune response that can contribute to tissue damage and disease when improperly activated. Dianthus’ lead product candidate, DNTH103, is an investigational, fully human monoclonal antibody designed to selectively inhibit C1s, a key protein in the classical complement pathway. The company is evaluating DNTH103 as a potential treatment for complement-mediated disorders, including generalized myasthenia gravis and immune-mediated neuropathies such as chronic inflammatory demyelinating polyneuropathy. The company was established to advance next-generation complement-targeted therapies intended to offer durable activity and convenient administration. Dianthus is headquartered in the United States and conducts clinical development activities aimed at serving patients with serious autoimmune diseases in major global healthcare markets.View Dianthus Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?Advanced Micro Devices' Q3 Results Answer a Big Question, But Another Remains3 Dividend Increases Above 10%, But Which Offers the Most Income?High Voltage Returns: Talen Energy Powers the Data Center RushBloom Energy: The Off-Grid Answer to AI's Power DrainWhy ExxonMobil and Chevron Reminded Investors to Keep it SimpleEnergy Transfer's Earnings Miss May Be Hiding Its Strongest Advantage Upcoming Earnings Airbnb (11/5/2026)Sony (11/5/2026)Toyota Motor (11/5/2026)Monster Beverage (11/5/2026)Canadian Natural Resources (11/5/2026)ConocoPhillips (11/5/2026)EOG Resources (11/5/2026)Targa Resources (11/5/2026)TC Energy (11/5/2026)Becton, Dickinson and Company (11/5/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
